hypericin has been researched along with Experimental Neoplasms in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the effect of co-injecting unlabelled hypericin (Hyp) on biodistribution, necrosis uptake and tumour retention of iodine-123 or iodine-131 labelled hypericin ((123/131)I-Hyp), a necrosis avid agent for an anticancer radiotherapy." | 3.80 | Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations. ( Chen, F; Cona, MM; Feng, Y; Li, J; Ni, Y; Oyen, R; Verbruggen, A; Witte, Pd, 2014) |
| " Avastin (bevacizumab), a vascular endothelial growth factor (VEGF) specific monoclonal antibody in combination with chemotherapy is offering hope to patients with metastatic colorectal cancer." | 1.34 | Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. ( Bhuvaneswari, R; Chee, SK; Olivo, M; Yuen, GY, 2007) |
| "Hypericin is a potent agent in the photodynamic therapy of cancers." | 1.33 | Elucidation of the tumoritropic principle of hypericin. ( Agostinis, P; de Witte, PA; Roskams, T; Van de Putte, M; Vandenheede, JR, 2005) |
| "Hypericin is a potent agent in the photodynamic therapy of cancers and accumulates to a large extent in tumor tissue." | 1.33 | The impact of aggregation on the biodistribution of hypericin. ( Bormans, G; De Witte, PA; Roskams, T; Van De Putte, M; Verbruggen, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (75.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cona, MM | 1 |
| Li, J | 1 |
| Feng, Y | 1 |
| Chen, F | 1 |
| Verbruggen, A | 2 |
| Witte, Pd | 1 |
| Oyen, R | 1 |
| Ni, Y | 1 |
| Urla, C | 1 |
| Armeanu-Ebinger, S | 1 |
| Fuchs, J | 1 |
| Seitz, G | 1 |
| Buríková, M | 1 |
| Bilčík, B | 1 |
| Máčajová, M | 1 |
| Výboh, P | 1 |
| Bizik, J | 1 |
| Mateašík, A | 1 |
| Miškovský, P | 1 |
| Čavarga, I | 1 |
| Delaey, E | 2 |
| Zupko, I | 2 |
| Chen, B | 3 |
| Derycke, A | 1 |
| van Laar, F | 1 |
| De Vos, D | 1 |
| De Witte, P | 2 |
| Van de Putte, M | 2 |
| Roskams, T | 3 |
| Vandenheede, JR | 2 |
| Agostinis, P | 2 |
| de Witte, PA | 4 |
| Zhou, Q | 1 |
| Olivo, M | 2 |
| Lye, KY | 1 |
| Moore, S | 1 |
| Sharma, A | 1 |
| Chowbay, B | 1 |
| Bormans, G | 1 |
| Bhuvaneswari, R | 1 |
| Yuen, GY | 1 |
| Chee, SK | 1 |
| Kamuhabwa, AR | 1 |
| D'Hallewin, MA | 1 |
| Baert, L | 1 |
| Xu, Y | 1 |
| Blank, M | 1 |
| Mandel, M | 1 |
| Hazan, S | 1 |
| Keisari, Y | 1 |
| Lavie, G | 1 |
1 trial available for hypericin and Experimental Neoplasms
| Article | Year |
|---|---|
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Anthracenes; Antineoplastic Agents; Chemotherapy, | 2005 |
11 other studies available for hypericin and Experimental Neoplasms
| Article | Year |
|---|---|
Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations.
Topics: Animals; Anthracenes; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Carriers; Fi | 2014 |
Successful in vivo tumor visualization using fluorescence laparoscopy in a mouse model of disseminated alveolar rhabdomyosarcoma.
Topics: Animals; Anthracenes; Apoptosis; Fluorescence; In Situ Nick-End Labeling; Laparoscopy; Mice; Mice, I | 2015 |
Hypericin fluorescence kinetics in the presence of low density lipoproteins: study on quail CAM assay for topical delivery.
Topics: Administration, Topical; Animals; Anthracenes; Biological Assay; Cell Line, Tumor; Chorioallantoic M | 2016 |
Comparison of hexamethylhypericin and tetrabromohypericin to hypericin for their in vivo efficacy as PDT tools.
Topics: Animals; Anthracenes; Antineoplastic Agents; Blood Proteins; Female; Humans; Lymphoma; Mice; Mice, I | 2003 |
Elucidation of the tumoritropic principle of hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents; Caco-2 Cells; Carbocyanines; Carbon Radioisotopes; Fema | 2005 |
The impact of aggregation on the biodistribution of hypericin.
Topics: Animals; Anthracenes; Cell Line, Tumor; Female; Injections, Intravenous; Liver; Lung; Metabolic Clea | 2006 |
Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins.
Topics: Angiogenic Proteins; Animals; Anthracenes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized | 2007 |
Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model.
Topics: Animals; Anthracenes; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Dru | 2000 |
In vivo photodynamic activity of hypericin in transitional cell carcinoma bladder tumors.
Topics: Animals; Anthracenes; Antineoplastic Agents; Carcinoma, Transitional Cell; Female; Injections, Intra | 2001 |
Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model.
Topics: Animals; Anthracenes; Antineoplastic Agents; Dermatitis, Phototoxic; Disease Models, Animal; Female; | 2001 |
Anti-cancer activities of hypericin in the dark.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Survival; Darkness; Female; Male; Mice; Mice, Inbr | 2001 |